RxDoctor Payments Data

Trista Borg, APRN

Family · North Platte, NENPI 1306494075

Payments from drug & device makers

$925in general payments, 2019–2025

Across 60 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$155
  • Novo Nordisk$151
  • Pfizer$99
  • E.r. Squibb & Sons, L.L.C.$87
  • Boehringer Ingelheim$83
  • Exact Sciences$69
  • plus $282 from 9 others

What the payments were for

  • Food & beverage$925100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$925 in reported general payments places this provider in the 70th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$75,450
Medicare patients
319
Services billed
1,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$41,325
EliquisApixaban49$28,889
JardianceEmpagliflozin46$22,273
MyrbetriqMirabegron41$20,997
XareltoRivaroxaban25$13,961
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$10,186
MultaqDronedarone Hcl13$9,025
FarxigaDapagliflozin Propanediol13$7,600
GlyxambiEmpagliflozin/Linagliptin13$7,449
TrintellixVortioxetine Hydrobromide14$6,440
LinzessLinaclotide13$6,196
Breo ElliptaFluticasone/Vilanterol16$6,159
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,546
Rasagiline Mesylate13$3,374
Atorvastatin Calcium198$2,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$151$41,32547 claims
PfizerEliquis, Paxlovid$99$30,25069 claims
Boehringer IngelheimJardiance, Glyxambi$83$29,72159 claims
Sanofi-aventis U.S. LLCMultaq$20$9,02513 claims
AbbVieLinzess$66$6,19613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 809 family providers in Nebraska.

Other family in North Platte

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →